Dexmed/Buspirone Synergism on Shivering
只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
The Cleveland Clinic
临床试验: NCT00334360
BioSeek: nct00334360
关键词
抽象
The purpose of this research is to determine if the combination of buspirone and dexmedetomidine are effective as a treatment to induce therapeutic hypothermia.
The design of the study includes four study days done in random order. The days are as follows: 1) Control (no drug); 2) Buspirone 60 mg orally; 3) Dexmedetomidine (delivered by a computer-controlled IV infusion to a target plasma concentration of 0.6 ng/ml); and, 3) the combination of buspirone 60 mg and dexmedetomidine (target plasma concentration of 0.6 ng/ml). a 20 cm-long catheter will be inserted into a cubital vein using standard aseptic technique In addition to the PIC line catheter, a simple peripheral catheter will be inserted into the other arm for drug administration.
Throughout the study period, mean-skin temperature will be maintained at 31°C by adjusting the temperature of circulating water (Cincinnati Sub-Zero, Cincinnati, OH) and forced-air warmers (Augustine Medical, Inc., Eden Prairie, MN). Furthermore, the back, upper-body, and lower-body will individually be maintained at the designated skin temperature. Lactated Ringer's solution cooled to ≈3°C will be infused via the PIC-line at rates sufficient to decrease tympanic membrane temperature ≈1.5°C/h. Fluid will be administered as long as oxygen consumption or electromyographic intensity (see below) continues to increase or a total of 5 liters of fluid is given. Heart rate will be measured continuously using an electrocardiogram; blood pressure will be determined oscillometrically at 5 min intervals at the ankle. In case heart rate and/or blood pressure changes unexpectedly (by more than 30% of the baseline), the study will stop and the volunteer will be re-warmed immediately.
日期
最后验证: | 05/31/2016 |
首次提交: | 06/05/2006 |
提交的预估入学人数: | 06/05/2006 |
首次发布: | 06/06/2006 |
上次提交的更新: | 06/26/2016 |
最近更新发布: | 06/28/2016 |
实际学习开始日期: | 08/31/2004 |
预计主要完成日期: | 07/31/2007 |
预计完成日期: | 07/31/2007 |
状况或疾病
Hypothermia
干预/治疗
Drug: 1
Drug: 2
Drug: 3
Drug: Control
相
相 4
手臂组
臂 | 干预/治疗 |
---|---|
Experimental: 1 dexmedetomidine | Drug: 1 Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia |
Experimental: 2 Buspirone | Drug: 2 Buspirone, 60 mg orally, will be given during controlled hypothermia. |
Experimental: 3 Buspirone and dexmedetomidine | Drug: 3 the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia |
Placebo Comparator: Control No drug | Drug: Control No drugs given during controlled hypothermia |
资格标准
有资格学习的年龄 | 18 Years 至 18 Years |
有资格学习的性别 | Male |
接受健康志愿者 | 是 |
标准 | Inclusion Criteria: - 18-40 years - normal weight (BMI <35) - healthy Exclusion Criteria: - obese (BMI >35) - taking any drugs - thyroid disease, dysautonomia, or Raynaud's syndrome - severe claustrophobia |
结果
主要结果指标
1. Shivering threshold [3 hours]
2. maximum intensity of shivering [3 hours]
3. gain of shivering [3 hours]
次要成果指标
1. hemodynamic responses [3 hours]